The first Food and Drug Administration approvals for cell and gene therapies are already more than a year out, but 2019 is likely to be a significant year for the field, particularly in areas like international interest, industry consolidation and pricing. That was the theme of a panel discussion Monday morning at Biotech Showcase in San Francisco, which coincides with the 2019 J.P. Morgan Healthcare Conference.
Image: Alliance for Regenerative Medicine CEO Janet Lambert speaks at the 2019 Biotech Showcase - https://medcitynews.com
